- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04206631
Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris
Effectiveness of Comedone Extraction and Oral Doxycycline In The First Line Treatment of Moderate Acne Vulgaris: Study on HIF-1 Alpha Expression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Acne vulgaris (AV) is a polymorphic disease, characterized by inflammatory and noninflammatory lesions. Systemic antibiotics play a role as the first line therapy of moderate acne vulgaris treatment. Since bacterial resistance tends to increase, alternative therapy for moderate acne vulgaris is needed.
This study aims to evaluate the effectiveness of comedone extraction compared to oral antibiotics as the main therapy of moderate acne vulgaris; and to etermine the expression of HIF-1 alpha by examining the immunohistochemistry and ELISA as a sign of hypoxia/anoxia in MAV lesion.
This was a randomized, placebo-controlled clinical trial that was performed in 2015 at three different dermatology clinics in Indonesia, Cipto Mangunkusumo Hospital Jakarta, Gatot Soebroto Army Hospital Jakarta, and PT. Mattel Indonesia, Cikarang.
One hundred and twenty eight subjects, aged between 15 and 50 years, with moderate acne vulgaris were recruited and randomized to receive either oral doxycycline (100 mg) or comedone extraction for six weeks. Subjects who had acne lesion and the back area were offered skin lesion biopsy to evaluate immunohistochemistry and ELISA before administration of medication.
At each follow-up visit, subjects were asked to grade the overall response and questioned regarding adverse events. The objective or main outcome was total reduction of inflammatory and noninflammatory lesions.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with moderate acne vulgaris based on clinical manifestation of face (20-100 comedones, 15-50 inflammatory lesions, and/or 30-125 total lesions)
- Age range of 15 to 50 years old
Exclusion Criteria:
- History of oral antibiotics consumption within 2 weeks preceding this study
- Usage of topical retinoid in less than previous 2 weeks
- History of systemic retinoid consumption within 3 months preceding this study
- Pregnant of breastfeeding women
- Consuming oral contraception during examination
- Drug allergy or skin manifestation due to side effect of moderate acne vulgaris first line therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Doxycycline Group
Subjects were randomized to receive Doxycycline capsules.
The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
|
Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
|
Active Comparator: Comedone Extraction Group
Subjects were randomized to receive comedone extraction.
Comedone extraction were done three times, and evaluated every 2 weeks.
|
Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Inflammatory Lesions at 2 weeks
Time Frame: 2 weeks
|
Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 2 inflammatory lesion count) __________________________________________________________ x 100% Baseline inflammatory lesion count |
2 weeks
|
Change from Baseline Inflammatory Lesions at 4 weeks
Time Frame: 4 weeks
|
Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 4 inflammatory lesion count) __________________________________________________________ x 100% Baseline inflammatory lesion count |
4 weeks
|
Change from Baseline Inflammatory Lesions at 6 weeks
Time Frame: 6 weeks
|
Numeric data of total reduction (improvement) of inflammatory lesions (Baseline inflammatory lesion count) - (Week 6 inflammatory lesion count) __________________________________________________________ x 100% Baseline inflammatory lesion count |
6 weeks
|
Change from Baseline Non-Inflammatory Lesions at 2 weeks
Time Frame: 2 weeks
|
Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 2 non-inflammatory lesion count) __________________________________________________________ x 100% Baseline non-inflammatory lesion count |
2 weeks
|
Change from Baseline Non-Inflammatory Lesions at 4 weeks
Time Frame: 4 weeks
|
Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 4 non-inflammatory lesion count) __________________________________________________________ x 100% Baseline non-inflammatory lesion count |
4 weeks
|
Change from Baseline Non-Inflammatory Lesions at 6 weeks
Time Frame: 6 weeks
|
Numeric data of total reduction (improvement) of non-inflammatory lesions (Baseline non-inflammatory lesion count) - (Week 6 non-inflammatory lesion count) __________________________________________________________ x 100% Baseline non-inflammatory lesion count |
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Improvement at 2 weeks
Time Frame: 2 weeks
|
Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement
|
2 weeks
|
Subjective Improvement at 4 weeks
Time Frame: 4 weeks
|
Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement
|
4 weeks
|
Subjective Improvement at 6 weeks
Time Frame: 6 weeks
|
Improvement of clinical manifestation based on subjective complaints. Subjects were asked to grade overall response using rating scale (0-4), with higher score means a better outcome (0) no or minimal improvement
|
6 weeks
|
Number of Participants with Side Effects at 2 weeks
Time Frame: 2 weeks
|
|
2 weeks
|
Number of Participants with Side Effects at 4 weeks
Time Frame: 4 weeks
|
|
4 weeks
|
Number of Participants with Side Effects at 6 weeks
Time Frame: 6 weeks
|
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expression of Antibody HIF-1 Alpha with Immunohistochemistry Examination
Time Frame: Baseline
|
Analysis of HIF-1 Alpha expression on keratinocyte cell of pilosebaceous ducts (samples from skin lesion biopsy) was examined with immunohistochemistry using antibody HIF-1 alpha which was visualized with microscope and photographed to achieve qualitative data.
|
Baseline
|
Expression of Antibody HIF-1 Alpha with ELISA Examination
Time Frame: Baseline
|
The measurement of HIF-1 Alpha protein concentration in the sebaceous follicle ducts was conducted through ELISA examination with Cusabio Human Hypoxia-inducible factor
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Irma B Sitohang, MD, PhD, Fakultas Kedokteran Universitas Indonesia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ComExt
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Doxycycline Capsule
-
Felix Chikita Fredy, MDNational Cardiovascular Center Harapan Kita Hospital IndonesiaUnknownHeart Failure | ST Elevation Myocardial Infarction | Anterior Wall Myocardial Infarction | Remodeling, VentricularIndonesia
-
Cadrock Pty. Ltd.Centre for Digestive Diseases, AustraliaTerminatedCoronary Heart Disease | Chlamydophila Pneumoniae InfectionsAustralia
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaboratorsActive, not recruitingHereditary Hemorrhagic Telangiectasia (HHT)Canada
-
Warner ChilcottCompletedUrogential Chlamydia Trachomatis InfectionUnited States
-
University of Maryland, BaltimoreNational Institute on Aging (NIA)CompletedAneurysmUnited States
-
Ahmadu Bello University Teaching HospitalRecruitingInfertility, Female | Pelvic Inflammatory DiseaseNigeria
-
Harold WiesenfeldNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPelvic Inflammatory DiseaseUnited States
-
Thomas GardnerJuvenile Diabetes Research FoundationCompleted
-
National Taiwan University HospitalChina Medical University Hospital; Kaohsiung Medical University Chung-Ho Memorial... and other collaboratorsNot yet recruitingEarly Syphilis, Latent, Serological Relapse After Treatment
-
University of PittsburghTu Du HospitalCompleted